Lead Story
US wildlife agencies announce $35.5 million in grants to accelerate recovery of endangered and threatened species
The National Fish and Wildlife Foundation and the U.S. Fish and Wildlife Service announced on October 21 that they are awarding $35.5 million in grants to fund conservation practices aimed at speeding the recovery of endangered and threatened species across the United States. The funded projects support actions that could eventually allow species to be downlisted from endangered to threatened status, or delisted entirely once populations are considered recovered. The grants add to a broader body of federal and philanthropic funding aimed at translating decades of habitat protection and species-monitoring work into measurable recovery milestones for imperiled wildlife.
Read more →Lead Story
US wildlife agencies announce $35.5 million in grants to accelerate recovery of endangered and threatened species
The National Fish and Wildlife Foundation and the U.S. Fish and Wildlife Service announced on October 21 that they are awarding $35.5 million in grants to fund conservation practices aimed at speeding the recovery of endangered and threatened species across the United States. The funded projects support actions that could eventually allow species to be downlisted from endangered to threatened status, or delisted entirely once populations are considered recovered. The grants add to a broader body of federal and philanthropic funding aimed at translating decades of habitat protection and species-monitoring work into measurable recovery milestones for imperiled wildlife.
ESA's Euclid space telescope, built to map galaxies, stumbles onto its first comet discovery
The European Space Agency's Euclid space telescope, launched in 2023 to map the large-scale structure of the universe, has made an unplanned discovery: a previously unknown comet, spotted in images taken in mid-September and confirmed by the Minor Planet Center on October 8 as C/2026 S1 (Euclid). The find was made by Mikko Pöntinen, a PhD student at the University of Helsinki working with the Euclid Consortium's Solar System Objects Science Working Group, while combing the telescope's deep-field data for faint moving objects. The comet sits roughly 1.3 billion kilometres from Earth on a long, little-studied orbit; ESA says the speed with which it was identified suggests Euclid could help spot comets while they are still far from the Sun, a capability that could benefit the agency's planned Comet Interceptor mission.
Read more →ESA's Euclid space telescope, built to map galaxies, stumbles onto its first comet discovery
The European Space Agency's Euclid space telescope, launched in 2023 to map the large-scale structure of the universe, has made an unplanned discovery: a previously unknown comet, spotted in images taken in mid-September and confirmed by the Minor Planet Center on October 8 as C/2026 S1 (Euclid). The find was made by Mikko Pöntinen, a PhD student at the University of Helsinki working with the Euclid Consortium's Solar System Objects Science Working Group, while combing the telescope's deep-field data for faint moving objects. The comet sits roughly 1.3 billion kilometres from Earth on a long, little-studied orbit; ESA says the speed with which it was identified suggests Euclid could help spot comets while they are still far from the Sun, a capability that could benefit the agency's planned Comet Interceptor mission.
Phase 3 trial finds rusfertide eases symptoms and cuts need for blood draws in patients with polycythemia vera
Results from the Phase 3 VERIFY trial, reported October 21, found that adding rusfertide to standard-of-care therapy improved clinical response, reduced the need for therapeutic phlebotomy, and eased symptom burden in patients with polycythemia vera, a chronic blood disorder that causes the bone marrow to overproduce red blood cells. Patients with the condition typically require frequent blood draws to manage dangerously high red-cell counts, a burdensome and only partially effective standard treatment. The trial's results point toward a more effective add-on therapy that could reduce how often patients need those procedures while better controlling the disease, offering a meaningful improvement in day-to-day quality of life for people living with the disorder.
Read more →Phase 3 trial finds rusfertide eases symptoms and cuts need for blood draws in patients with polycythemia vera
Results from the Phase 3 VERIFY trial, reported October 21, found that adding rusfertide to standard-of-care therapy improved clinical response, reduced the need for therapeutic phlebotomy, and eased symptom burden in patients with polycythemia vera, a chronic blood disorder that causes the bone marrow to overproduce red blood cells. Patients with the condition typically require frequent blood draws to manage dangerously high red-cell counts, a burdensome and only partially effective standard treatment. The trial's results point toward a more effective add-on therapy that could reduce how often patients need those procedures while better controlling the disease, offering a meaningful improvement in day-to-day quality of life for people living with the disorder.
India's tigers, lions and rhinos buck the trend as WWF's global wildlife report highlights conservation gains
WWF and the Zoological Society of London's Living Planet Report 2026, released October 8, found that monitored wildlife populations fell by an average of 73% worldwide between 1970 and 2022, but the report singled out India as a bright spot where sustained conservation investment is paying off. India's tiger population has rebounded to roughly 3,682 animals as of its most recent census, giving the country more than 75% of the world's wild tigers, while Asiatic lions in Gujarat grew from 674 in 2020 to 891 in the 2025 census, a 32% rise attributed to continuous scientific monitoring and local community support. Greater one-horned rhinoceros numbers have also expanded in protected habitats such as West Bengal's Jaldapara and Gorumara national parks and Assam's Pobitora Wildlife Sanctuary, where grassland management, invasive weed removal and anti-poaching patrols have stabilised and grown the population. The report's authors frame these recoveries as evidence that, where it is properly funded and sustained, conservation works even amid a bleak global picture.
Read more →India's tigers, lions and rhinos buck the trend as WWF's global wildlife report highlights conservation gains
WWF and the Zoological Society of London's Living Planet Report 2026, released October 8, found that monitored wildlife populations fell by an average of 73% worldwide between 1970 and 2022, but the report singled out India as a bright spot where sustained conservation investment is paying off. India's tiger population has rebounded to roughly 3,682 animals as of its most recent census, giving the country more than 75% of the world's wild tigers, while Asiatic lions in Gujarat grew from 674 in 2020 to 891 in the 2025 census, a 32% rise attributed to continuous scientific monitoring and local community support. Greater one-horned rhinoceros numbers have also expanded in protected habitats such as West Bengal's Jaldapara and Gorumara national parks and Assam's Pobitora Wildlife Sanctuary, where grassland management, invasive weed removal and anti-poaching patrols have stabilised and grown the population. The report's authors frame these recoveries as evidence that, where it is properly funded and sustained, conservation works even amid a bleak global picture.
New trial data strengthen case that an experimental drug can protect vision after optic neuritis
Swiss biopharmaceutical company Oculis reported new Phase 2 biomarker data on October 22 further supporting the neuroprotective potential of privosegtor, an experimental treatment for acute optic neuritis, a condition in which inflammation damages the optic nerve and can cause lasting vision loss. The data showed lower blood markers of nerve injury in patients treated with privosegtor compared with placebo, reinforcing earlier results from the randomized ACUITY trial that found treated patients gained an average of 18 ETDRS letters of visual function at three months with no drug-related serious side effects. Privosegtor already holds orphan drug designation from both the US FDA and the European Medicines Agency, as well as FDA Breakthrough Therapy designation, and is now being tested further in the ongoing PIONEER-1 trial.
Read more →New trial data strengthen case that an experimental drug can protect vision after optic neuritis
Swiss biopharmaceutical company Oculis reported new Phase 2 biomarker data on October 22 further supporting the neuroprotective potential of privosegtor, an experimental treatment for acute optic neuritis, a condition in which inflammation damages the optic nerve and can cause lasting vision loss. The data showed lower blood markers of nerve injury in patients treated with privosegtor compared with placebo, reinforcing earlier results from the randomized ACUITY trial that found treated patients gained an average of 18 ETDRS letters of visual function at three months with no drug-related serious side effects. Privosegtor already holds orphan drug designation from both the US FDA and the European Medicines Agency, as well as FDA Breakthrough Therapy designation, and is now being tested further in the ongoing PIONEER-1 trial.